Zoe A Hughes

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders
    Zoe A Hughes
    Wyeth Research, Discovery Neuroscience, Princeton, New Jersey 08543, USA
    Curr Mol Pharmacol 2:215-36. 2009
  2. doi WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent
    Zoe A Hughes
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 54:1136-42. 2008
  3. doi The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists
    Wayne E Childers
    Chemical Sciences, Pfizer Global Research and Development, Princeton, New Jersey 08543 8000, USA
    J Med Chem 53:4066-84. 2010
  4. doi WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
    Julie A Brennan
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 332:190-201. 2010
  5. ncbi Differentiating antidepressants of the future: efficacy and safety
    Sharon Rosenzweig-Lipson
    Wyeth Discovery Neuroscience, Depression and Anxiety, CN 8000, Princeton, NJ 08543, USA
    Pharmacol Ther 113:134-53. 2007
  6. doi Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
  7. doi 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists
    Kevin G Liu
    Wyeth Research, CN 8000, Princeton, New Jersey 08543, United States
    J Med Chem 53:7639-46. 2010
  8. doi 5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats
    Stacey J Sukoff Rizzo
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Int J Neuropsychopharmacol 12:1045-53. 2009
  9. pmc Innovative approaches for the development of antidepressant drugs: current and future strategies
    Lee E Schechter
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    NeuroRx 2:590-611. 2005
  10. doi Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
    Warren D Hirst
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 325:134-45. 2008

Detail Information

Publications12

  1. ncbi Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders
    Zoe A Hughes
    Wyeth Research, Discovery Neuroscience, Princeton, New Jersey 08543, USA
    Curr Mol Pharmacol 2:215-36. 2009
    ..In particular we will highlight the molecular mechanisms and signal transduction pathways most likely underlying the effects of estrogen in the CNS...
  2. doi WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent
    Zoe A Hughes
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 54:1136-42. 2008
    ....
  3. doi The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists
    Wayne E Childers
    Chemical Sciences, Pfizer Global Research and Development, Princeton, New Jersey 08543 8000, USA
    J Med Chem 53:4066-84. 2010
    ....
  4. doi WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
    Julie A Brennan
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 332:190-201. 2010
    ..Furthermore, WS-50030 provides a tool to further explore how combining these mechanisms might differentiate from other antipsychotics or antidepressants...
  5. ncbi Differentiating antidepressants of the future: efficacy and safety
    Sharon Rosenzweig-Lipson
    Wyeth Discovery Neuroscience, Depression and Anxiety, CN 8000, Princeton, NJ 08543, USA
    Pharmacol Ther 113:134-53. 2007
    ..This review will discuss the many facets of differentiation and potential strategies for the development of novel antidepressants...
  6. doi Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
    ..A selective OTR antagonist also failed to block the effects of OT on immobility in the TST. The significance of these findings for shaping the clinical development of OTR agonists is discussed...
  7. doi 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists
    Kevin G Liu
    Wyeth Research, CN 8000, Princeton, New Jersey 08543, United States
    J Med Chem 53:7639-46. 2010
    ..The synthesis, SAR, and pharmacokinetic and pharmacological activities of some of the compounds including 3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole (WAY-255315 or SAM-315) will be described...
  8. doi 5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats
    Stacey J Sukoff Rizzo
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Int J Neuropsychopharmacol 12:1045-53. 2009
    ..Taken together, these data suggest that 5-HT(1A) antagonist treatment may have utility for the management of SSRI-induced sexual dysfunction...
  9. pmc Innovative approaches for the development of antidepressant drugs: current and future strategies
    Lee E Schechter
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    NeuroRx 2:590-611. 2005
    ..The present review addresses the most exciting approaches and reviews the localization, neurochemical and behavioral data that provide the supporting rationale for each of these targets or target combinations...
  10. doi Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
    Warren D Hirst
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 325:134-45. 2008
    ..These results further support the rationale for use of this compound class in the treatment of cognitive dysfunction associated with psychiatric and neurological conditions...
  11. ncbi Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples
    Mei Yi Zhang
    Chemical and Screening Sciences, Princeton, Wyeth Research, NJ 08543, USA
    J Pharm Biomed Anal 44:586-93. 2007
    ..Collectively, these biological data provided in vivo validation of this analytical method...
  12. doi Innovations in CNS drug discovery: differentiating strategies to treat depression
    Chad E Beyer
    Depression and Anxiety Research, Discovery Neuroscience, Wyeth, Princeton, NJ 08543, USA 1 732 274 4852 1 732 274 4755
    Expert Opin Drug Discov 2:1369-77. 2007
    ....